The bioabsorbable stent as a virtual prosthesis

The Lancet

Volumn 373, Issue 9667, 2009, Pages 869-870

  Colombo, Antonio ^a,b   Sharp, Andrew SP ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b EMO GVM CENTRO CUORE COLUMBUS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; MAGNESIUM; POLYLACTIC ACID; POLYLACTIDE;

ADVERSE OUTCOME; ARTERY DIAMETER; ARTERY LESION; ARTICLE; BARE METAL STENT; BIODEGRADABLE IMPLANT; BIOSORPTION; CARDIOVASCULAR RISK; CORONARY ARTERY; CORONARY STENT; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG SOLUBILITY; DRUG WITHDRAWAL; EQUIPMENT DESIGN; HUMAN; INTIMA; MATERIAL COATING; MITOSIS INHIBITION; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; STENT THROMBOSIS; TISSUE GROWTH;

EID: 61849094324     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60521-3     Document Type: Note

References (11)

1. Tanguay J.F., Zidar J.P., Phillips III H.R., and Stack R.S. Current status of biodegradable stents. Cardiol Clin 12 (1994) 699-713
2. Tamai H., Igaki K., Kyo E., et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102 (2000) 399-404
3. Serruys P.W., Ormiston J.A., Onuma Y., et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373 (2009) 897-910
4. Serruys P.W., de Jaegere P., Kiemeneij F., et al., for the Benestent Study. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 331 (1994) 489-495
5. Sigwart U., Puel J., Mirkovitch V., Joffre F., and Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316 (1987) 701-706
6. Moses J.W., Leon M.B., Popma J.J., et al., for the SIRIUS. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
7. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
8. Colombo A., and Karvouni E. Biodegradable stents: "fulfilling the mission and stepping away". Circulation 102 (2000) 371-373
9. Erbel R., Di Mario C., Bartunek J., et al., for the PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting with Absorbable Metal Stents). Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369 (2007) 1869-1875
10. Ormiston J.A., Serruys P.W., Regar E., et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371 (2008) 899-907
11. Windecker S., Serruys P.W., Wandel S., et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372 (2008) 1163-1173